Logo Université Laval Logo Université Laval
International Chair on Cardiometabolic Risk
My Healthy Waist

Documentation centre

1669-1680 of 2022 results
Page 140 of 169
Key Publications February 13, 2012

Novel developments in omega-3 fatty acid-based strategies.

Curr Opin Lipidol 2011;22:437-44

Davidson MH, Kling D, Maki KC
Lipids/Lipoproteins Nutrition
Key Publications February 13, 2012

Statins and the risk of new-onset diabetes: a review of recent evidence.

Curr Opin Lipidol 2011;22:460-6

Preiss D, Sattar N
Diabetes Lipids/Lipoproteins
Key Publications February 10, 2012

Low- and high-dose plant and marine (n-3) fatty acids do not affect plasma inflammatory markers in adults with metabolic syndrome.

J Nutr 2011;141:2166-71

Dewell A, Marvasti FF, Harris WS, Tsao P, Gardner CD
Inflammation Lipids/Lipoproteins Metabolic Syndrome
Key Publications February 3, 2012

Cardiology in 2011--amazing opportunities, huge challenges.

JAMA 2011;306:2158-9

Peterson ED, Gaziano JM
Hypertension Lipids/Lipoproteins
Key Publications February 3, 2012

High-density lipoprotein cholesterol as the Holy Grail.

JAMA 2011;306:2153-5

Cannon CP
Lipids/Lipoproteins
Key Publications February 3, 2012

Statin therapy in primary CVD prevention remains a hot-button topic for some.

JAMA 2011;306:2077-8

Mitka M
Lipids/Lipoproteins Prevention
Key Publications February 2, 2012

Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial.

JAMA 2011;306:2099-109

Nicholls SJ, Brewer HB, Kastelein JJ, Krueger KA, Wang MD, Shao M, Hu B, McErlean E, Nissen SE
Lipids/Lipoproteins
Key Publications January 27, 2012

Comparison of two methods using plasma triglyceride concentration as a surrogate estimate of insulin action in nondiabetic subjects: triglycerides x glucose versus triglyceride/high-density lipoprotein cholesterol.

Metabolism 2011;60:1673-6

Abbasi F, Reaven GM
Insulin Resistance Lipids/Lipoproteins
Key Publications January 26, 2012

Evacetrapib is a novel, potent, and selective inhibitor of cholesteryl ester transfer protein that elevates HDL cholesterol without inducing aldosterone or increasing blood pressure.

J Lipid Res 2011;52:2169-76

Cao G, Beyer TP, Zhang Y, Schmidt RJ, Chen YQ, Cockerham SL, Zimmerman KM, Karathanasis SK, Cannady EA, Fields T, Mantlo NB
Hypertension Lipids/Lipoproteins Metabolism: Animal Studies
Key Publications January 26, 2012

Nascent HDL formation by hepatocytes is reduced by the concerted action of serum amyloid A and endothelial lipase.

J Lipid Res 2011;52:2255-61

Wroblewski JM, Jahangiri A, Ji A, de Beer FC, van der Westhuyzen DR, Webb NR
Inflammation Lipids/Lipoproteins Metabolism: Animal Studies
Key Publications January 19, 2012

Adipose modulation of high-density lipoprotein cholesterol: implications for obesity, high-density lipoprotein metabolism, and cardiovascular disease.

Circulation 2011;124:1602-5

McGillicuddy FC, Reilly MP, Rader DJ
Adipose Tissue Lipids/Lipoproteins
Key Publications January 19, 2012

Adipose tissue ATP binding cassette transporter A1 contributes to high-density lipoprotein biogenesis in vivo.

Circulation 2011;124:1663-72

Chung S, Sawyer JK, Gebre AK, Maeda N, Parks JS
Adipose Tissue Lipids/Lipoproteins Metabolism: Animal Studies
of 169